<ѻýҕl>SGLT2 Inhibitor Eases Symptoms for HFpEF Patientsѻýҕl> Trial suggests hard outcomes not the only ones helped by this class of medication Sep 13, 2021
<ѻýҕl>Second-Gen Drug for HCM Emerges, Nipping at Mavacamten's Heelsѻýҕl> Novel cardiac myosin inhibitor is headed for a phase III trial Sep 12, 2021
<ѻýҕl>Heart Failure's 'Golden Moment' Not Translating into Better Healthѻýҕl> Problems of implementation and health equity persist Sep 12, 2021
<ѻýҕl>Feared ARNI Effect on Cognition Hasn't Come to Fruitionѻýҕl> Neurocognitive protection by sacubitril/valsartan suggested instead by observational study Sep 12, 2021
<ѻýҕl>Virtual Heart Failure Care No Substitute for the Face-to-Face Visit?ѻýҕl> Reduced GDMT titration suggests a dip in quality of care Oct 05, 2020
<ѻýҕl>Phrenic Nerve Stimulation Holds Up for Central Sleep Apneaѻýҕl> Apnea indices, daytime sleepiness improved over 5 years Oct 05, 2020
<ѻýҕl>Translational Research: Diet Affects the Heart in Multiple Waysѻýҕl> Inflammation, circadian rhythm, and beyond Sep 16, 2019
<ѻýҕl>Shared Decision-Making: Cardiologists Moving Through the Stages of Griefѻýҕl> Rules from CMS for ICDs, LAA closure feels arbitrary, some say Sep 16, 2019
<ѻýҕl>Study: LVAD Surgical Technique Can be Further Refinedѻýҕl> Left ventricular assist device outflow cannula angulation, anastomosis size may be important Sep 15, 2019
<ѻýҕl>Debate: Is LVEF Really that Important in Heart Failure?ѻýҕl> Benefit of identifying preserved, reduced, mid-range, supranormal EF under question Sep 14, 2019
<ѻýҕl>Drop in Long-Term Stroke Complications with Newer LVADѻýҕl> Data show even "mild" strokes are far from benign, though Sep 19, 2018
<ѻýҕl>For HFpEF, Better Heart-Lung Connection with Albuterolѻýҕl> Beta-agonist associated with improved exercise hemodynamic measures Sep 17, 2018
<ѻýҕl>HF Monitor Trips on PA Injury in Postmarket Surveillanceѻýҕl> Reintervention or device recalibration often needed after PA injury Sep 18, 2017
<ѻýҕl>HFSA: Clinical Benefits Tied To Lung Monitoring Persistѻýҕl> HF rehospitalization, deaths remain reduced up to 4.5 years Sep 21, 2016
<ѻýҕl>Cardiac Myosin Activator Shows Promise for LV Functionѻýҕl> 'More hands pulling on the rope' Sep 21, 2016
<ѻýҕl>HFSA: Treat to NT-proBNP Target Flops in Trialѻýҕl> Outcomes no better with treatment aimed at 30% reduction Sep 20, 2016
<ѻýҕl>HFSA: Did LAP Monitoring Cut HF Rehospitalizations?ѻýҕl> LAPTOP-HF investigators tried to make sense of terminated study Sep 19, 2016
<ѻýҕl>HFSA: Controversy Highlighted at Upcoming Meetingѻýҕl> BOSTON -- Much progress has been made in managing heart failure, but there are still some areas of controversy that will be highlighted at the upcoming meeting of the Heart Failure Society of America here. Sep 16, 2011